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ABSTRACT 
 
Fahr's disease (FD) or Fahr’s syndrome is characterized by basal ganglia calcification with clinical manifestations 
in the form of neuropsychiatric disorders, neurological symptoms, and cognitive symptoms. FD commonly affects 
young to middle aged adults. The etiology of this syndrome does not identify a specific agent. Clinical 
manifestations of this disease incorporate a wide variety of symptoms. The diagnostic criteria of Fahr’s Syndrome 
consist of bilateral calcification of basal ganglia, progressive neurologic dysfunction, absence of biochemical 
abnormalities, infectious, traumatic, and a significant family history. Medical imaging techniques for the diagnosis 
consist of computed tomography (CT), magnetic resonance imaging (MRI), and plain radiography of the skull. This 
paper presents a case of Fahr’s syndrome in a 60-year-old married prisoner with antisocial personality and 
seizures. Furthermore, CT and MRI scans showed bilateral symmetric calcifications in the basal ganglia 
calcification (BGC) and dentate nuclei, cerebellum, and centrum semiovale. 
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INTRODUCTION 
 
Fahr’s disease (FD) (Fahr’s disease or Idiopathic Basal Ganglia Calcifications) is an uncommon neurodegenerative 
disorder that is characterized by abnormal deposition of calcium in areas of the brain that controls the movements, 
including basal ganglia, thalamus, dentate nucleus, cerebral cortex, cerebellum, subcortical white matter, and 
hippocampus (1-3). The clinical manifestations of FD incorporate a wide variety of symptoms Trautner et al., in 
1988 suggested that bilateral calcifications are needed with neuropsychiatric and extrapyramidal disorders together 
with normal calcium and phosphorus metabolism (4). In parallel, another study by Beall et al., in 1989 reported that 
seizures, rigidity, and dementia disorders correlated with calcification of the basal ganglia (1). In correlation with 
FD, Flint and Goldstein, 1992 revealed that radiologists may view basal ganglia calcification (BGC) as a chanceful 
finding (5). In addition, Rasmussen et al. exhibited that incidental discovery of BGC in individuals less than 50 
years old may be used to the diagnostic investigation (6). On the other hand, in 1991, Nishiyama et al. reported that 
the course of mentioned disease is progressive(7). Diagnostic criteria of this disease consist of bilateral calcification 
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of basal ganglia, progressive neurologic dysfunction, absence of biochemical abnormalities,  an infectious, traumatic 
and a significant family history(8). A study conducted by Manyam et al. suggested that in adult-onset FD and 
calcium deposition generally begins in the third decade of life together with neurological deterioration two decades 
later, however, BGC can also occur in pediatric populations (9). Investigations demonstrated that the most usual site 
of involvement are the basal ganglia and dentate nucleus together with extra pyramidal signs associated with 
hyperparathyroidism (2). Initiating calcification induced defective iron transport and free radical production, which 
may cause damage tissue (1, 2). Reduction of blood flow to calcified area associates with clinical symptoms (10). 
Clinical signs can be developed in the progressive deterioration of mental function, loss of previous motor 
development, spastic paralysis, optic atrophy, and athetosis(4). Histologically concentric calcium deposits within the 
walls of small and medium-sized arteries are present. Less frequently the veins may also be affected. Droplet 
calcifications can be observed along capillaries. These deposits may eventually lead to the closure of the lumina of 
vessels. The pallidal deposits stain positively for iron (11). Diffuse gliosis may surround the large deposits, but 
significant loss of nerve cells is rare. On electron microscopy the mineral deposits appear as amorphous or 
crystalline material surrounded by a basal membrane (12). Calcium granules are seen within the cytoplasm of 
neuronal and glial cells. The calcifications seen in this condition are indistinguishable from those secondary to 
hyperparathyroidism or other causes (11). Medical imaging techniques for the diagnosis consist of CT, MRI, and the 
plain radiograph of the skull (13). Clinical other finding includes blood and urine testing for hematologic and 
biochemical indices (8). It has been suggested that early diagnosis and treatment can reverse the calcification 
process leading to complete recovery of mental functions(8). 
 
Case presentation 
The patient was a 60-year-old married man living in Kermanshah who were referred to Kermanshah Imam Reza 
(AS) Hospital from Kermanshah Central Prison due to dyspnea and nonproductive cough and being hospitalized 
with a primary diagnosis of COPD and CHF in December 2011. The first manifestations of his disease appeared 
from 3 days ago with dyspnea and chest pain, which were worsening during physical activities. During the rest, the 
patient had dyspnea, but its intensity was reduced. The patient has not reported but has mentioned the history of lung 
disease since 1996. The patient has also mentioned no specific drug history, but had the history of using smoke and 
drugs and his family had no history of a specific disease. The patient has been imprisoned three times since 2007. 
During a physical examination, his blood pressure, heart pulse, respiration rate, and body temperature were 130/80 
mm Hg, 100 per min, 20 breaths per min and 37 C, respectively. The patient was alert during early examinations and 
pale conjunctiva, rales in chest and + 2 pitting edema in limbs were the only positive finding in the early 
examinations of patient. The clinical and blood sample assessments showed anemia and normal sodium, potassium 
and troponin, and International Normalized Ratio (INR) = 1.6 and C-reactive protein (CRP) = +3, as well as evident 
ischemic variations in electrocardiograph (ECG). The patient was transferred to ICU because of dyspnea with the 
possibility of pulmonary edema. Furthermore, the performed assessments, showed normal AST, ALT, D-Dimer, 
ANA, Ds DNA, HBS Ag, Anti HCV, HBC Ab, HIV, C-ANCA, P-ANCA, whereas the calcium and PTH levels 
were lower than normal, and the patient had Ca = 3.3 mg/dl (normal range= 8.3-11mg/dl), P=9.1 mg/dl (normal 
range= of 2.5-5 mg/dl) and PTH=3.2pg/dl ( normal range= 8.8-76.6 pg/ml) and normal thyroid tests. The 
echocardiography assessment showed, EF=50%, MR=++, TR=++, mild RV dysfunction, mild PH and PAP=40-45 
mmHg. Abdominal and pelvic ultrasonography showed a normal size for kidneys, slightly increased in cortico-
medullary echo (Isoechoic to liver) and normal cortical thickness and pyelocaliceal system was organized, which 
can be a normal finding regarding the patient age. Stone and hydronephrosis were not observed in the scans and 
other internal organs had normal observed. Generalized tonic-clonic seizure appeared in the patient 15 days after 
hospitalization, thus he was admitted for brain computed tomography (CT) scan. In the performed non-contrastive 
CT scan, midline shift and space-occupying lesion were not observed and the ventricular system had normal view. 
Furthermore, bilateral symmetric calcifications in the basal ganglia and dentate nuclei, cerebellum and white matter 
of bilateral centrum semiovale as well as bilateral occipital lobe gyruses were observed. Regarding the above 
clinical and neuroimaging manifestations, the Fahr’s syndrome was diagnosed for the patient. The consciousness 
level of the patient gradually decreased and because of severe respiratory distress and pulmonary edema, he was 
intubated, but finally the patient died. 
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Figure 1. 60 year old male with Fahr’s syndrome. CT axial images, at the level of the cerebellum showing hyperdens area (calcification). 
Spiral CT scan, axial, 5 mm slice, KVP 1.4, exposure 300 
 
 
 
Figure 2. 60 year old male with Fahr’s syndrome. CT axial images, at the level of the third ventricular showing hyperdens area 
(calcification) in caudate and lenticular nucleus and thalamus. Spiral CT scan, axial, 5 mm slice, KVP 1.4, exposure 300 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 60 year old male with Fahr’s syndrome. MRI axial T2 images at the of low ventricular level showing hypointense area 
(calcification) in the region of the basal ganglia (arrow). MRI: 1 Tesla magnet, T2 axial image (TE= 94, TR= 9000), 5 mm slice 
 
 
 
Figure 4. 60 year old male with Fahr’s syndrome. MRI coronal T2 images, at the level of body of lateral ventricle showing hypointense 
area (calcification) in the region of the basal ganglia (arrow). MRI: 1 Tesla magnet, T2 sagittal image (TE= 99, TR= 3000), 5 mm slice 
 
DISCUSSION 
 
FD which was first introduced by Karl Theodor Fahr in 1930 (14) is a rare neurological degenerative disease 
characterized by the presence of bilateral symmetric calcifications over the basal ganglia, dentate nuclei, cerebellum 
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as well as bilateral centrum semiovale. In this disease, abnormal deposit of calcium (calcification) in areas of brain 
controlling movement (basal Ganglia and cerebral cortex) causes the loss of related cells, and this disease is 
associated with normal serum levels of calcium and phosphorus in patient (15). Basal ganglia and dentate nucleus 
are the most common sites of involvement and most of patients manifest extrapyramidal symptoms. The disease is 
often associated with abnormal phosphocalcemic metabolism especially with hypoparathyroidism(16). 
 
Etiology & Demographics 
The exact etiological manifestations remain unknown yet but an association with specific etiologies include 
endocrine disorders (e.g. hypoparathyroidism and Hyperparathyroidism), adult onset neurodegenerative conditions 
(e.g. neurodegeneration, iron accumulation disease, polycystic lipomembranous and leukoencephalopathy), 
infectious disease (e.g. cockayne syndrome Types 1 and 2), and Inherited or early onset syndrome (e.g. Aicardi-
Goutieres syndrome, Tuberous sclerosis complex, Brucellosis, and Coat's disease) (8). Defective iron transport and 
free radicals production initiate calcification process. FD in adults initiates with generalized deposit of calcium in 
the third decade and neurological complications become manifest after two decades. Disease symptoms develop 
when deposits are accumulated and include progressive complications of brain function, loss of prior motor 
movements, spastic paralysis and athetosis. Optic atrophy may also occur (16).  
 
Clinical & Imaging Findings 
These patients refer in their youth with psychosis symptoms (hallucinations, delusions) similar to schizophrenia (17) 
and symptoms of dementia and movement disorders as Parkinsonism, athetosis chorea and negative symptoms of 
schizophrenia are seen in their older ages (17, 18). Low IQ is another symptom of this syndrome. Coincidence of 
this syndrome with Down syndrome has also been reported in the performed study (17). FD is diagnosed based on 
the presence of symmetric calcifications involving basal ganglia (bilateral striopallidodentate calcinosis - BSPDC) 
with normal serum levels of calcium and phosphorus (19).This disease is distinguished from Fahr’s syndrome in 
which basal ganglia calcifications have specific causes (such as hypoparathyroidism) and also from normal 
calcifications in the basal ganglia without clinical symptoms and known reason, which is an incidental finding 
observed in 0.7 to 0.9 percent of populations and mainly in ages over 60 (20). The most common sites of 
calcification are putamen, caudate nucleus, internal capsule, dentate nucleus, cerebellum, thalamus, and cerebellar 
white matter. Calcium deposit occurs in extracellular and extravascular space surrounding the capillaries (15). FD 
can be associated with a wide variety of clinical symptoms including psychotic disorders, seizure and dementia but 
other symptoms such as syncope and pseudo hypoparathyroidism have also been observed. Benke et al. studied 
brain metabolism of a patient with Fahr’s syndrome with dementia of the frontal lobe and dominant frontal lobe 
syndrome manifestations using F-18 FDG Positron Emission Tomography (PET). Dramatic reduction of glucose 
metabolism in basal ganglia and frontal lobe including orbito-frontal and anterior cingulate regions were consistent 
with psychotic and personality disorder symptoms of the disease (8, 21) (Table 1). An autosomal dominant 
inheritance was observed in familial cases in genetic studies (22). A polygene inheritance is identified by linking to 
the IBGC1 locus on chromosome 14q, but the causative gene is not known yet. CT scan is the most effective way of 
screening in adults (23). No distinct psychiatric and neurological symptoms were observed in the first-degree 
relatives of patient. Although the subjects undergo CT scan, radiologic signs of disease may be present in them. 
Additionally, most frequently affected area is the lenticular nucleus, especially the internal globuspallidus while 
Cerebellar gyri, brain stem, centrum semiovale, and subcortical white matter may also affected. Calcifications in the 
putamen, thalami, caudate, and dentate nuclei are also common. Occasionally, calcium deposits begin or 
predominate in regions outside the basal ganglia. Calcification seems to be progressive and gradual. 
 
Treatment & prognosis 
FD is a rare disease with no absolute treatment and the aim is an adjunctive therapy. Therefore, more rapid diagnosis 
of it with imaging techniques is recommended. L-dopa (or carbidopa) and antipsychotic drugs are prescribed for 
Parkinson and psychotic symptoms, respectively. Furthermore, Seizures and movement disorders in Fahr’s 
syndrome which are related to the parathyroid disorder can be resolved with the correction of phosphate and calcium 
levels for e.g. treatment with alpha hydroxy vitamin D3 and corticosteroids reversed neurological deficits (24). To 
summarize, though Fahr’s syndrome and FD are rare entities they should be suspected in patients with 
neuropsychiatric disturbances and seizure disorder. Routine biochemical investigations should always be performed 
to rule out metabolic causes. Conversely, all patients with incidentally detected striopallidodentate calcinosis should 
be subjected to thorough neuropsychiatric examination and if required, biochemical tests. Knowledge of the 
associated conditions will not only help to rectify the treatable cause but will also prevent unnecessary treatment in 
others. There have been many major advances in our understanding of Fahr’s syndrome, especially in terms of 
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etiology, the breadth of the disease phenotype and diagnostic methods. There is no simple solution to this dilemma 
and controversy. Certainly more qualitative and quantitative data on the experience of families are needed. Their 
voice - while reflecting one aspect of the whole portrait - is crucial and vital. Secondly, international consensus on 
guidelines for care that includes all of the specialties involved in the care of children and elder people with Fahr’s 
syndrome is required. Thirdly, Continuation of the now ongoing dialogue on this topic by neurologist, geneticists, 
psychiatrist, families, and the appropriate care specialists is mandatory and welcomed. Has been suggested the 
pathophysiological mechanisms leading to bilateral calcification. Only rare data are available on the early events 
leading to bilateral calcification. Furthermore, physicians play a crucial role the effective treatment of the disease. 
Currently, available medications are either poorly effective and/or have bad tolerance. 
 
Table 1. Clinical features of Fahr's syndrome could vary with the age and course of disease (8). 
 
System Clinical properties 
1 Neurological 
Loss of consciousness 
Tetany 
Seizures 
Epileptic disorder 
Gait disorder 
Spasticity 
Speech impairment 
Dementia 
Myoclonus 
Coma 
Paroxysmal choreoathetosis 
Dystonic choreoathetosis 
Papilledema of intracranial 
hypertension 
Pleocytosis of CSF 
2 Movement disorder 
Clumsiness 
Fatigability 
Unsteady gait 
Involuntary movements and 
muscle cramping 
3 Neuropsychiatric features 
Psychosis 
Depression 
Apoplexia 
Deterioration of intelligence 
Inability to make decisions 
 
CONCLUSION 
 
Although the clinical symptoms of this disease are mostly as motion and cognitive disorders, depression and 
psychosis resulting from it are rather common. Parkinsonism, chorea, dystonia, tremor, gait disorders, dysarthria, 
seizures, and myoclonus are the most common neurological picture and fronto-subcortical type is the cognitive 
impairment picture. It is observed that the patient has been jailed repeatedly due to antisocial behaviors. This 
behavior and personality of the patient, especially in older ages may be caused by this syndrome. The diagnosis of 
Fahr’s syndrome requires the presence of certain clinical criteria that may confuse the diagnosis with other aspects. 
New treatment methods need to be discovered and employed to reduce functionality associated with the disease. It's 
especially important to consider genetic counseling of known at risk parents before conception. Screening 
asymptomatic individuals has not been able to demonstrate immediate medical benefits in adults or young 
individual's. The screening of young individuals is considered unnecessary, can have profound psychological harm 
effects. 
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